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Abstract
Verve, an oral nicotine delivery product (ONDP), was introduced by Nu Mark (Altria Client 
Group, Richmond VA) for smokers to use in places where smoking is prohibited. This study 
assessed the effect of this ONDP on plasma nicotine levels, heart rate, product satisfaction, and 
ability to suppress smoking urge and cigarette cravings. Thirteen daily cigarette smokers [8 men 
and 5 women; average age 33.4 years] attended two laboratory sessions, one occurred after 
overnight tobacco abstinence. Plasma samples were collected before and after ONDP use and 
measured for nicotine. In non-abstinent smokers, mean plasma nicotine levels increased from 18.3 
to 21.0 ng/mL. In abstinent smokers, average nicotine levels increased from 3.1 to 4.5 ng/mL. 
After overnight tobacco abstinence, ONDP use significantly (p < 0.01) increased heart rate from 
69 beats per minute (bpm) to 75 bpm; while urge to smoke decreased significantly (p < 0.01) from 
a score of 8.6 to 4.9. Participants indicated moderate product satisfaction that was not changed by 
tobacco abstinence. Analysis of unused ONDP revealed total nicotine levels of 1.68 ± 0.09 mg/
disc. Spent ONDP discs were also analyzed to determine % nicotine liberated during chewing; 
results were 80% in the non-abstinent and 82% in the abstinent conditions (ns). Our study results 
indicate that ONDP use can increase plasma nicotine levels and heart rate and reduce cigarette 
cravings in abstinent smokers.
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1. Introduction
In recent years the tobacco industry has introduced a number of new tobacco products 
marketed to smokers as cigarette alternatives in situations where tobacco smoking is 
prohibited (e.g. workplace, airplanes, public places). The use of these products may involve 
oral administration or inhalation of a substance aerosol (e.g., Electronic Nicotine Delivery 
systems (ENDs)) rather than tobacco combustion (Palazzolo, 2013). Some examples of these 
products include snus, a low nitrosamine product that originated in Sweden (Stepanov et al., 
2012), and dissolvable products that consist of compressed tobacco with added flavorings 
that fully dissolve in the mouth, (e.g. Camel Sticks, Strips and Orbs) (Rainey et al., 2011; 
Connolly et al., 2010) or dissolves from a solid support, such as a toothpick (Marlboro 
Tobacco Sticks; Skoal Tobacco Sticks). Although some smokers quit tobacco products 
altogether using novel oral use products, many smokers may use alternate products 
concurrently with their typical smoked products; thus preventing or delaying tobacco 
cessation and resulting in continued exposure to both nicotine and other toxicants 
(Palazzolo, 2013).
In 2012, an ONDP called Verve was introduced and continues to be sold in test markets in 
Virginia by NuMark, a company associated with Altria Client Group (Philip Morris). This 
spit-free product is a nondissolving, solid polymer disc containing non-tobacco cellulose 
fibers, flavorings and reportedly 1.5 mg of tobacco-derived nicotine that is released to users 
when the disc is chewed (Liu et al., 2013). This ONDP product has similar characteristics as 
medicinal nicotine products such as nicotine gum sold for smoking cessation.
The ONDP utilizes a nicotine-embedded matrix to provide buccal absorption similar to 
formulations of nicotine polacrilex (gum). Oral tobacco products may have public health 
consequences in nonsmokers and smokers who use these products (Tomar, 2007). Use of 
moist snuff has been shown to initiate cigarette smoking (Tomar and Giovino, 1998) and the 
use of oral tobacco products may postpone cessation attempts (Tomar, 2003; Connolly et al., 
1986; Agaku et al., 2013). The present study assessed pharmacologic effects (nicotine 
delivery) and cardiovascular parameters (heart rate and blood pressure), and performed 
qualitative assessment of perceptions, health risks, and ability to suppress smoking urge and 
cigarette cravings in daily cigarette smokers. Furthermore, ONDP discs were characterized 
according to several physical (disc weight, % moisture) and chemical parameters (pH, total 
nicotine and calculated nonprotonated nicotine). Nicotine content and pH are particularly 
important measures because they directly affect the quantity and speed of nicotine 
absorption (Fant et al., 1999; Pickworth et al., 2014; Benowitz et al., 1987, 1988).
The Food and Drug Administration (FDA) is currently considering scientific data relevant to 
its regulatory authority over tobacco products, particularly ones such as ONDP that are not 
specifically mentioned in the Family Smoking Prevention and Tobacco Control Act 
(FSPTCA) (Public Law 111-31, 2009). These types of products are marketed as alternatives 
to cigarettes; however, some nicotine-dependent users may continue smoking while using 
these products in settings where smoking is prohibited or unacceptable.
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2. Materials and methods
2.1. Participants
Thirteen daily cigarette smokers (8 males; 7 African Americans, 6 Whites) participated in 
this study. The average age of the participants was 33.4 (range: 21–52). The participants 
smoked an average of 16.9 ± 3.5 cigarettes/day (CPD) with a range of 10–20 CPD. The 
smokers in this study had smoked regularly for an average of 15 ± 9.4 years (range: 3–31 
years). None of the participants had used this ONDP prior to the study and none were 
current users of oral tobacco products. Their most commonly used cigarette brands were: 
Newport (8), Marlboro (2), Camel (1), L&M (1), and Maverick (1). All participants smoked 
filtered cigarettes (10 smoked menthol and 3 smoked non-menthol). Participants had 
moderate to strong levels of nicotine dependence as indicated by the average Fagerström 
Test for Nicotine Dependence (Heatherton et al., 1991) of 5.8 ± 2.1 (range 1–8); a score of 5 
or greater is generally indicative of nicotine dependence. Data were collected between 
December 2012 and February 2013 at Battelle's Human Exposure Assessment Laboratory 
(Baltimore, MD).
2.2. Oral nicotine delivery product (ONDP)
The ONDP discs used in the present study were purchased from a convenience store in the 
Fredericksburg, VA area in October of 2012. According to product marketing materials, the 
product contains approximately 1.5 mg of tobacco-derived nicotine. The ONDP is sold in a 
plastic tube containing 16 discs each. The mint-flavored ONDP discs are flat, Reuleaux 
triangular-shaped with a dimension of approximately 3 mm (thickness) × 15 mm × 12 mm 
and weigh 500 mg.
2.3. Product measurements of total and non-protonated nicotine
Nicotine concentrations in unchewed and chewed discs were measured by gas 
chromatography–mass spectrometry (GC/MS) in selected ion monitoring (SIM) mode as 
described elsewhere (Stanfill et al., 2009) with slight modifications to extraction conditions, 
which are described below. In order to validate the extraction efficiency, nicotine from 
unchewed ONDP discs was extracted under standard and modified conditions. It was 
determined that samples were most thoroughly extracted after sonication for 3 h at 60 °C; 
these modified parameters were used to analyze all of the ONDP disc samples. The pH 
measurements, required for calculating non-protonated nicotine, were made using a Sirius 
Vinotrate pH robot (Sirius Analytical Ltd., East Sussex, UK), which adds a 5-mL aliquot of 
distilled, deionized water to each sample and makes temperature-corrected pH 
measurements. Product pH was the averaged value of pH measurements at 5, 15, 30 and 60 
min. Calculations for the percentage of nicotine as non-protonated nicotine were taken from 
the Federal Register (Federal Register, 1999). Nicotine values (total and non-protonated) are 
expressed as mg/disc. The ONDP discs were also analyzed for minor alkaloids (nornicotine, 
mysomine, anatabine, and anabasine) to assess whether the nicotine is synthetic or purified 
from tobacco. Minor alkaloid analysis was performed using GC/MS/MS according to a 
previously published method (Lisko et al., 2013). The method limits of detection (LODs) for 
the minor alkaloids are 0.08, 0.04, 0.12 and 0.12 µg/g for nornicotine, myosmine, anabasine 
and anatabine, respectively.
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2.4. Methods and procedure
Research volunteers were screened for eligibility and interest in the study during a telephone 
interview. Potential participants were invited to the laboratory and assessed for general 
health and the accessibility of an arm vein for blood draws, and also screened for 
concomitant medications. Participants signed a consent form that had been reviewed and 
approved by the Battelle Institutional Review Board and were paid a total of $150 for the 
two visits. A Research Determination Form was completed for this activity and it was 
determined that the role of the Centers for Disease Control (CDC) did not constitute 
engagement in human subject research.
Participants made two visits to the clinic: the first when they were allowed to use tobacco 
before the session and the second after overnight tobacco abstinence where they were 
prohibited from using tobacco or nicotine products. During clinical visits, participants were 
seated in a comfortable chair. Eating, drinking and smoking were prohibited during the 
session. Exhaled carbon monoxide (CO) was collected at the beginning of the session. After 
a 5 minute rest, baseline heart rate (HR) and blood pressure (BP) readings were recorded 
and the participant completed the Questionnaire on Smoking Urges short form (QSU) (Cox 
et al., 2001). A butterfly needle was inserted in an arm vein and a blood sample was 
collected. The ONDP was given to the participants who chewed it ad lib for 15 min as 
directed by the labeled instructions of the manufacturer. At 5 and 10 minute marks, HR was 
recorded. At the end of the 15 min, the participant removed the spent ONDP and placed it 
into a tube that was refrigerated. HR, BP and exhaled CO were recorded and another blood 
sample was collected. The participant answered Visual Analog Scale questionnaires, Product 
Satisfaction Scale and Risk Perception Questions. The procedure at the second visit was 
identical except that the participant must have been tobacco abstinent for at least 12 h as 
verified by an exhaled CO level below 13 ppm. Following their collection, samples 
(unchewed and chewed discs) were shipped to CDC on dry ice for analyses.
2.5. Dependent measures
2.5.1. Physiologic measures—HR and BP were recorded before, during (5, 10 min) and 
at the conclusion of ONDP use using a finger pulse oximeter unit and an automated monitor 
(DRE Waveline Plus Vital Signs Monitor [DRE, Inc., Louisville, KY]). In order to verify 
overnight abstinence from tobacco and other combustible products, exhaled CO levels were 
determined before and after ONDP use using a Breath CO monitor (Vitalograph, Lenexa, 
KS). Plasma samples were taken from a 7 mL blood draw before and within 5min after the 
15 minute-ONDP use period. Blood plasma was generated by centrifugation and stored 
frozen until analysis by Labstat International, LLC (Kitchener, Ontario). The nicotine limit 
of quantification (LOQ) of LabStat's TME-00001 method was 4.1 ng/mL; the limit of 
detection (LOD) was 1.2 ng/mL. For sample values between LOD and LOQ, the level was 
estimated from extrapolation from the standard curve [LabStat, personal communication].
2.6. Subjective measures
Before and after ONDP administration, participants completed the brief form (10 questions) 
of the QSU (Cox et al., 2001). The QSU yields a Total Score (overall craving) and Factor 1 
(craving defined by anticipation of positive effects of smoking) and Factor 2 (craving 
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derived from anticipated relief of tobacco withdrawal discomfort). Product satisfaction was 
assessed by four Visual Analog Scale questions that measured “strength”, “liking”, “head 
rush”, and “alert”. The participant indicated their endorsement by placing a mark on a line 
anchored by the phrases “not at all” and “extremely”. The response was the percentage of 
the entire line (0 to 100). A 16-item questionnaire derived from items from the Cigarette 
Evaluation Scale (CES) (Westman et al., 1992) and the Duke Sensory Questionnaire (DSQ) 
(Behm and Rose, 1994) were used to assess product liking and effects. All questions were 
answered on a 1 to 7 scale (1 = not at all; 7 = extremely). Perceptions of the health risk of 
the ONDP were assessed using five questions: “I think it would be safe to use”; “I would 
buy it”; “compared to your usual brand of cigarettes ONDP contains more, less about the 
same nicotine (or don't know)”; “more, less or equally safe or don't know”; and “would the 
ONDP make it easier to quit smoking”. The Minnesota Withdrawal Scale (Hughes et al., 
1991) is a multiple item standard test for the severity of signs and symptoms associated with 
tobacco withdrawal.
3. Results
3.1. ONDP characteristics
To characterize the ONDP, the Tobacco and Volatiles Branch, Division of Laboratory 
Sciences at the Centers for Disease Control (CDC) and Prevention measured the ONDP 
discs for several physical (disc weight, % moisture) and chemical parameters (pH, total 
nicotine and calculated non-protonated nicotine) (Table 1). All measured values are 
presented on a per disc basis. The average weight of the ONDP discs was 493 mg and each 
disc had an average moisture content of 8.4%. The measured value of total nicotine (1.68 
mg) is 11% higher than the stated value of 1.5 mg on the product website (NuMark website, 
2014). The aim of the analysis was to measure the maximum extractable nicotine.
Using the Henderson–Hasselbalch equation, the percentage of nicotine in the non-protonated 
form for the unchewed discs was calculated to be 22.0% (0.37 mg/disc). In unchewed discs 
from freshly opened packs, the average aqueous pH was 7.47. Chewed discs from 
participants who did not finish the protocol were available for pH analysis. The pH values 
from four partially chewed samples ranged from pH 7.31 to 7.92; at those pH values, the 
percent of nicotine in the nonprotonated form ranged from 16.2 to 44.2%.
3.2. ONDP nicotine release
Spent discs were analyzed from participants in the non-abstinent (Visit 1) and abstinent 
(Visit 2) conditions. As shown in Table 2, total nicotine liberated (removed by chewing) 
from the chewed discs ranged from 0.83 to 1.68 mg/disc, which corresponds to 49.2–100% 
total nicotine liberated upon use.
Table 2 shows the amount of nicotine retained in the ONDP discs after chewing. Nine 
participants had results above the limit of detection; the data from one participant was 
incomplete and not included in the analysis. In both the abstinent and non-abstinent 
conditions, a similar amount of nicotine (range of 0 to 0.85 mg/disc of nicotine) remained in 
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the disc after chewing. Across the nine participants the amount of nicotine released from the 
disc ranged from 49% to 100% (0.83–1.68 mg).
Exhaled CO values and plasma nicotine levels confirm that participants complied with the 
overnight tobacco restrictions. Average exhaled CO values on the non-abstinent day (26.9 
ppm) and abstinent day (6.6 ppm) were significantly different (p < 0.05). As shown in Fig. 1, 
decreases in plasma nicotine levels were observed on the abstinent day. After overnight 
tobacco abstinence, plasma levels of nicotine decreased from an average of 18.3 ± 6.3 
ng/mL to 3.1 ± 2.0 ng/mL (p < 0.01). The ONDP delivered nicotine in quantities sufficient 
to raise plasma nicotine levels by 2.7 and 1.4 ng/mL in the non-abstinent and abstinent 
conditions, respectively. There was a statistically significant (p < 0.05) decrease in the mean 
heart rate before ONPD use on the abstinent day (69 ± 5 bpm) compared to the heart rate 
before ONDP on the non-abstinent day (75 ± 8 bpm) (Fig. 2). After ONDP use on the 
abstinent day, heart rate rapidly and significantly increased to levels similar to the resting 
heart rate observed on the non-abstinent day.
Overnight tobacco abstinence significantly increased scores on the Minnesota Nicotine 
Withdrawal Scale from an average of 8.8 ± 5.5 to 13.0 ± 9.6 (p < 0.05). Overnight tobacco 
abstinence led to significant increases in cigarette craving. Average scores for Factors 1 and 
2 and Total Score of the QSU significantly increased at baseline of the abstinent compared to 
the non-abstinent day. After use of the ONDP on the abstinent day there was a significant 
reduction in tobacco craving on all metrics: 5.5 (initial) vs 3.7 (post-use) for Factor 1, (p < 
0.05); 3.1 vs. 1.3 (Factor 2, p < 0.01), and 8.6 vs 4.9 (Total Score, p < 0.01). However, the 
ONDP-induced reductions in QSU scores were not significant on the non-abstinent day.
Responses to a series of subjective questionnaires indicated moderate liking and 
acceptability of the product; the subjective assessments did not change during the abstinent 
condition. For example, on the 5-point scales of whether they would purchase the ONDP, the 
average response was between “not certain” and “maybe”; likewise, the product was less 
acceptable if it were the same price as cigarettes. Compared to their usual cigarette 
participants indicated that ONDP delivers the same amount of nicotine and that they were 
about as “safe” as cigarettes. There were no significant differences in the ONDP product 
evaluation on the non-abstinent and abstinent days. On a scale of 0 to 100, the average value 
for ‘liking’ this products was 42.1; the perceived strength rating averaged 67.2. The product 
was perceived as ‘strong’ (Participants 28, 21, 2, and 9) by those subjects with the highest 
nicotine extraction and higher nicotine boost (0.8–3.6 ng/mL). It was liked most by two 
people (Participants 9 and 21) who had disc extractions of 87 and 93% and had increases of 
plasma nicotine levels of 0.8 and 3.6 ng/mL, respectively.
4. Discussion
Tobacco lozenges, dissolvable tobacco products and ENDs have been introduced and 
marketed as products that can be used by smokers in situations where smoking is prohibited. 
The ONDP examined in the present report is unique because it is marketed by a tobacco 
company as a substitute for cigarettes; whereas, other oral nicotine-only products are sold by 
pharmaceutical companies for the purpose of smoking cessation. A public health concern is 
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that nicotine delivery products such as ONDPs and ENDs that relieve craving in abstinent 
situations or in situations where combustible smoking is not allowed may reduce the 
motivations of smokers to quit (Palazzolo, 2013).
In the present study, we found that the ONDP delivered small amounts of nicotine. The 
increase in plasma nicotine after 15 min of use averaged 2 ng/mL and was similar in both 
tobacco-abstinent and non-abstinent participants. These results indicate a similar extraction 
efficiency regardless of the cigarette craving. The increase in plasma nicotine was similar in 
magnitude to that seen with other tobacco products 1.5-mg Ariva and 4-mgStonewall 
(Kotlyar et al., 2007), prototype ONDP products (Liu et al., 2013), and the 2-mg nicotine 
gum (Lunell and Lunell, 2005; Benowitz et al., 1987), but smaller than plasma nicotine 
levels after a lozenge containing 4-mg of nicotine (Kotlyar et al., 2007). The increase in 
plasma nicotine after the ONDP is much less than the 11 ng/mL increase typically observed 
after cigarette smoking (Williams et al., 2010) or after conventional moist snuff use where 
plasma levels increased between 4.2 and 19.5 ng/mL (Fant et al., 1999; Kotlyar et al., 2007; 
Pickworth et al., 2014).
Although the increase in plasma nicotine levels after ONDP use was quite small compared 
to cigarette smoking, the ONDP caused significant increases in heart rate in tobacco-
abstinent participants. The increase in heart rate of about 6 beats per minute (bpm) was 
similar in magnitude to that seen after nicotine gum use but less than the 10 to 12 bpm 
increase following cigarette use in nicotine-deprived smokers (Benowitz et al., 1988). Also, 
despite the small increases in plasma nicotine, a decrease in cigarette craving occurred. The 
marketing of the ONDP is directed at the momentary relief of tobacco cravings and smoking 
urges. The data from the present study support reduced cigarette craving as measured by the 
decrease in QSU scores. Nicotine polacrilex, (Nicorette™ gum), also temporarily decreases 
tobacco cravings and these effects are most evident when tobacco craving is increased after 
periods of tobacco deprivation (Houtsmuller et al., 2002; Kotlyar et al., 2007).
Participants reported ‘low’ to ‘moderate’ scores on scales of product liking and willingness 
to purchase the ONDP. However, ‘liking’ for a new product is typically quite low among 
established tobacco users that have self-selected a product from the vast array of oral and 
combustible tobacco products in the market (Chen et al., 2010; Borgerding et al., 2012). 
‘Liking’ scores for nicotine polacrilex are also typically quite low (Pickworth et al., 1986; 
Houtsmuller et al., 2002; Nemeth-Coslett et al., 1988). The limited and rather slow nicotine 
absorption from the ONDP and the low to moderate ratings on product ‘liking’ suggest an 
overall low to moderate risk of abuse from this ONDP — similar to that of other oral 
nicotine delivery products.
It is interesting to note that participants had the perception that ONDP delivered about the 
same amount of nicotine as their brand of cigarette even though the plasma nicotine boost 
was only 20% of the boost associated with cigarette smoking. Moreover, participants 
expressed no difference in this response whether asked on the abstinent or nonabstinent day. 
Ad lib use of the nicotine polacrilex (gum 2 mg) typically releases about 50% of its nicotine 
content (Pickworth et al., 1986) and increases plasma levels of nicotine by about 3 ng/mL 
(Lunell and Lunell, 2005; Kotlyar et al., 2007) whereas, the participants in the present study 
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were able to extract between 50 and 100% of the nicotine from their ONDP, suggesting that 
the formulation of this ONDP provides for a more efficient release of nicotine.
The discs were analyzed in triplicate forminor alkaloids and found to contain nornicotine, 
myosmine, anabasine and anatabine. Minor alkaloids were quantified using a recently 
developed GC/MS/MS analytical method (Lisko et al., 2013). Concentrations of minor 
alkaloids were found to be higher than the LOD for each analyte but below the lowest 
calibrator. The presence of nornicotine, mysomine, anatabine, and anabasine suggests that 
the nicotine present in this product is derived from a highly purified tobacco extract rather 
than a synthetic source. This is an important finding because the FDA is restricted by the 
FSPTCA to the regulation of tobacco products or products made from tobacco (Public Law 
111-31, 2009). The chemical analysis further support the notion that this ONDP is made 
from tobacco derived nicotine and may be subject to FDA regulation.
Limitations of the present study include using only a single dose of the ONDP, a relatively 
small number of participants and lack of a placebo condition. However, the results indicate 
that the ONDP delivers doses of nicotine capable of suppressing craving, and increasing 
heart rate in tobacco-abstinent smokers. It is difficult to accurately predict the amount of 
nicotine that was absorbed because physiological factors such as oral pH, saliva volume, 
buffering potential of saliva, and saliva swallowing vary among participants. In future 
studies, the measurement of salivary pH before and after ONDP use would be helpful in the 
interpretation of data.
5. Conclusions
Like the current dramatic increase in use of other non-traditional nicotine delivery products 
(e.g., ENDs) (Palazzolo, 2013), dissolvable tobacco (Rainey et al., 2011), and ONDP-like 
products pose important questions for tobacco control policy. In addition to delivery of 
nicotine, unique characteristics of the ONDP may also have public health implications — 
their use is easily concealed and the product is spit-less. These characteristics may increase 
the appeal of ONDP to people including pregnant women or youth, who may wish to 
conceal their nicotine use. Furthermore, because the ONDP provides for nicotine delivery in 
places where smoking is not allowed, they may subvert the effects of indoor smoking 
regulations that tend to increase smoking cessation (Hopkins et al., 2010). The ONDP 
delivered small levels of nicotine in this study, suggesting that these products will not fully 
satisfy cravings and may lead to ongoing or concurrent use of ONDP with other tobacco 
products. The ONDP could provide nicotine without use of combusted tobacco products; but 
low amounts of nicotine delivered to the user suggest that they could be a nicotine ‘bridge’ 
to the next cigarette. Therefore, use of ONDP or similar products may prevent people who 
might otherwise quit from achieving complete cessation.
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Fig. 1. 
ONDP plasma nicotine delivery in non-abstinent and abstinent conditions. White bar—
before chewing; gray bar—after chewing; *—difference before/after chewing in abstinent 
condition (p = .0566); † — difference before chewing in non-abstinent/abstinent condition 
(p < .01).
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Fig. 2. 
Heart rate during ONDP chewing (non-abstinent and abstinent conditions). Mean HR values 
with standard error are presented; PRE — base (resting) heart rate measured before 
chewing; 5 min, 10 min, and 15 min — HR measured in 5th and 10th minutes of chewing 
and immediately after 15 min of chewing; * — statistically significant difference between 
non-abstinent and abstinent conditions (p < 0.05); † — statistically significant difference 
before/after chewing in abstinent condition.
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Table 1
Measured values for disc weight, size dimensions, percent moisture, pH, % non-protonated nicotine, and total 
nicotine concentrations in unused ONDP discs.
Parameters for unused ONDP discs Average values (±SD)
Disc weight (mg)a 493.0 ± 12.8
Percent moisturea 8.40 ± 0.05
pHb 7.47 ± 0.09
Nicotine (mg/disc, stated on packaging)c 1.50
Measured total nicotine (mg/disc)b 1.68 ± 0.09
% of nicotine as non-protonated nicotine (at pH 7.47) 22.1%
Non-protonated nicotine (mg/disc at pH 7.47)b 0.37
ONDP = oral nicotine delivery product.
a
n = 5.
b
n = 4.
c
n = 3.
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Table 2
Visit 1 and Visit 2: ONDP discs chewed by non-abstinent/abstinent smokers. Amount of nicotine retained (mg) 
and % released from ONDP discs. The calculated values are based on a total nicotine value of 1.68 mg/disc.
Non-abstinenta Abstinent
Participant
number
Nicotine
(mg/disc)
% total
nicotine
Nicotine
(mg/disc)
% total
nicotine
Post-chewing Released Post-chewing Released
1 0.21 87% 0.24 86%
2 0.04 98% 0.08 95%
9 0.36 79% 0.14 92%
10 0.31 82% 0.25 85%
13 0.86 49% 0.75 55%
17 0.29 83% 0.23 86%
18 0.60 65% 0.84 50%
21 0.58 66% 0.30 82%
24 n.d. 100% 0.03 98%
28 n.d. 100% n.d. 100%
32 0.70 59% 0.68 59%
33 n.d. 100% n.d. 100%
Mean ± SD 0.34 ± 0.29 80 ± 18% 0.30 ± 0.29 82 ± 18%
ONDP = oral nicotine delivery product.
n.d. — not detectable.
For calculation purposes 0.5 × LOD = 0.025 mg/disc was used.
a
Participants were tested on one day without smoking restrictions (non-abstinent) and on another day after overnight tobacco abstinence 
(abstinent).
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